According to Ariba, Yamanouchi, the first Japanese-based pharmaceutical company to implement Ariba Buyer, is using the solution to centralize and streamline its
According to Ariba, Yamanouchi, the first Japanese-based pharmaceutical company to implement Ariba Buyer, is using the solution to centralize and streamline its
purchasing processes, reduce purchasing costs and cycles and benefit from
economies of scale purchasing. Yamanouchi employees have used the solution to
electronically purchase a variety of goods and services including lab equipment and supplies, business travel services and office equipment.
"Large, multi-national corporations such as Yamanouchi are ideally
positioned to reap significant benefits from Enterprise Spend Management, and
use it to provide an ongoing competitive edge," said Michael Schmitt, EVP and
Chief Marketing Officer, Ariba. "Along with our local partners, Ariba is
committed to helping Yamanouchi attain its spend management goals, and to add
the company to our growing list of worldwide pharmaceutical success stories
for excellence in spend management."
In a phased deployment, Yamanouchi commenced the Ariba Buyer rollout in
July this year at its head office and Hasune branch in Tokyo, and recently
extended the system to 12 domestic branches, four research laboratories, three
plants and most of its subsidiaries. The company plans to make new spend
commodities, such as contract and temporary labor services, available by the
end of 2002.
Kevin Appareti, global director for Medical Science Liaison at Philips Healthcare, explains how to motivate KOLs and how to measure their value
The Mobile Health Competition is now closed, but the journey is just beginning for the winning idea.
Phil Taylor reports on the commercial and scientific opportunities facing medical scientific liaisons (MSLs)
Alex Gochtovtt, principal with Cognizant’s enterprise analytics practice, discusses pharma’s social media opportunities and the importance of data analytics
An interview with Serkan Erkovan of Boehringer Ingelheim.
Ashok Bhaseen, Vice President of Sales & Marketing at Pediapharm reveals how his company establishes trust when engaging KOLs